Cargando…
Healthcare costs associated with short-acting β(2)-agonists in asthma: observational UK SABINA study
BACKGROUND: Poor asthma control is associated with high short-acting β(2)-agonist (SABA) use. AIM: To assess asthma-related healthcare resource utilisation (HCRU) and medication costs associated with high versus low SABA prescriptions in the UK. DESIGN & SETTING: Analysis of SABINA I (SABA use I...
Autores principales: | Attar-Zadeh, Darush, Capstick, Toby, Leese, Deborah, Arnetorp, Sofie, Rapsomaniki, Eleni, Da Costa, Keith Peres, Maslova, Ekaterina, Xu, Yang, Gibson, Danny, Quint, Jennifer K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Royal College of General Practitioners
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646192/ https://www.ncbi.nlm.nih.gov/pubmed/36759020 http://dx.doi.org/10.3399/BJGPO.2023.0015 |
Ejemplares similares
-
Short-acting β(2)-agonists and exacerbations in children with asthma in England: SABINA Junior
por: Morgan, Ann, et al.
Publicado: (2023) -
Short‐acting β(2)‐agonist use and asthma exacerbations in Swedish children: A SABINA Junior study
por: Melén, Erik, et al.
Publicado: (2022) -
SABINA: An Overview of Short-Acting β(2)-Agonist Use in Asthma in European Countries
por: Janson, Christer, et al.
Publicado: (2020) -
The Burden of Short-Acting β(2)-Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program
por: Di Marco, Fabiano, et al.
Publicado: (2021) -
Short-acting β(2)-agonist prescription patterns in patients with asthma in Turkey: results from SABINA III
por: Yorgancıoğlu, Arzu, et al.
Publicado: (2022)